113
Participants
Start Date
May 15, 2008
Primary Completion Date
November 30, 2009
Study Completion Date
November 23, 2009
vosaroxin
Vosaroxin was administered by slow intravenous (IV) infusion or via syringe pump within 10 minutes.Patients could have completed up to 4 treatment cycles consisting of 1 or 2 induction treatment cycles and up to 2 consolidation treatment cycles. For Schedule A, an induction cycle was a minimum of 21 days during which patients received vosaroxin on Days 1, 8, and 15, followed by weekly observations until hematologic recovery for patients with aplastic marrow after the postinduction bone marrow assessment. For Schedules B and C, an induction cycle was a minimum of 15 days, during which patients received vosaroxin on Days 1 and 8 (Schedule B), or Days 1 and 4 (Schedule C), followed by the same weekly observations until hematologic recovery as for Schedule A.
University of Pittsburgh Cancer Institute, Pittsburgh
Hollings Cancer Center at Medical University of South Carolina, Charleston
Vanderbilt-Ingram Cancer Center, Nashville
University of Mississippi Medical Center, Jackson
Indiana University Cancer Center, Indianapolis
St. Francis Hospital & Health Systems at Beech Grove Campus, Indianapolis
Rush University Medical Center, Chicago
The University of Chicago, Chicago
University of MO Ellis Fischel Cancer Center, Columbia
Cancer Center of Kansas, Wichita
Cancer Center of Kansas, Wichita
LSU Health Sciences Center at Shreveport, Shreveport
MD Anderson Cancer Center, Houston
Rocky Mountain Blood and Marrow Transplant Program, Denver
Huntsman Cancer Institute at the University of Utah, Salt Lake City
Mayo Clinic Hospital, Phoenix
Mayo Clinic Scottsdale, Scottsdale
Scripps Cancer Center, La Jolla
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston
Lead Sponsor
Sunesis Pharmaceuticals
INDUSTRY